Literature DB >> 7641437

Pulmonary resection for metastatic soft tissue sarcomas.

A Kawai1, H Fukuma, Y Beppu, R Yokoyama, R Tsuchiya, H Kondo, H Inoue.   

Abstract

The therapeutic results of pulmonary resection for metastatic soft tissue sarcomas were analyzed. From 1970 to 1992, 23 patients (15 male and 8 female) underwent 40 pulmonary resections for metastatic soft tissue sarcomas. Nine (39%) patients had multiple thoracotomies for recurrences (range, 2-6). The 5-year actuarial overall survival was 32% (median, 28 months). Statistical analysis showed that age, gender, location of primary tumor, histology, site of pulmonary metastasis, tumor doubling time, or chemotherapy did not impact on survival. Significant prognostic factors associated with improved survival (p < 0.05) included a disease-free interval, and completeness and extent of the initial pulmonary resection. Patients with disease-free intervals > or = 12 months survived longer (5-year survival, 48.5%) than patients with disease-free intervals < 12 months (12%). Patients who could be rendered free of disease at their initial thoracotomy, without extended chest-wall resection, achieved a better outcome (5-year survival, 44%) than the others (5-year survival, 0%).

Entities:  

Mesh:

Year:  1995        PMID: 7641437

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  Impact of Smoking History on Pulmonary Metastasis-free Survival in Patients With Soft-tissue Sarcoma.

Authors:  Masatake Matsuoka; Masanori Okamoto; Tamotsu Soma; Isao Yokota; Ryuta Arai; Tomohiro Onodera; Eiji Kondo; Norimasa Iwasaki; Hiroaki Hiraga
Journal:  Cancer Diagn Progn       Date:  2021-05-03

2.  Prognostic Factors of Pulmonary Metastasectomy for Soft Tissue Sarcomas Arising in the Trunk Wall and Extremities.

Authors:  Shizuhide Nakayama; Eisuke Kobayashi; Jun Nishio; Yu Toda; Masaya Yotsukura; Shun-Ichi Watanabe; Takuaki Yamamoto; Akira Kawai
Journal:  Cancers (Basel)       Date:  2022-07-08       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.